ORPHAZYME A/S - ADR (ORPH) Stock Price, Quote, News and Overview
NASDAQ:ORPH - Nasdaq - ADR
ORPH Quote, Performance and Key Statistics
0.87
-0.02 (-2.25%)
The current stock price of ORPH is 0.87 null. In the past month the price decreased by -28.1%. In the past year, price decreased by -89.88%.
ORPH Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.74 | 339.94B | ||
| AMGN | AMGEN INC | 14.22 | 158.77B | ||
| GILD | GILEAD SCIENCES INC | 14.17 | 136.38B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 120.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.81 | 61.30B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 41.07B | ||
| ARGX | ARGENX SE - ADR | 97.43 | 34.21B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.14B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.39 | 27.09B | ||
| NTRA | NATERA INC | N/A | 21.91B | ||
| BIIB | BIOGEN INC | 8.48 | 19.67B | ||
| INSM | INSMED INC | N/A | 18.63B |
Related stock screener links
About ORPH
Company Profile
Orphazyme A/S is a biopharmaceutical company, which engages in the development of treatment for patients living with life-threatening and debilitating rare diseases. The company develops new therapies for the treatment of a family of genetic disorders. The firm's main focus is on preclinical development of medicines for the treatment of lysosomal storage diseases (LSDs), a group of approximately 50 genetic disorders that result from deficiencies of lysosomal enzymes or other lysosomal components, and protein aggregation diseases. The Company’s candidate, arimoclomol, stimulates the production of the cells’ protein rescue system, the heat shock proteins, which helps the misfolded proteins to either get back to their functional shape or, if this cannot be achieved, remove them from the cells by means of the cells’ recycling system, the lysosomes, so they no longer form toxic aggregates. The firm collaborates with academic institutions in Europe and the United States.
Company Info
ORPHAZYME A/S - ADR
Ole Maaloees Vej 3, Copenhagen N
KOEBENHAVN DK-2200 DK
CEO: Anders Vadsholt
Employees: 180
Phone: 4539178272.0
ORPHAZYME A/S - ADR / ORPH FAQ
What is the stock price of ORPHAZYME A/S - ADR today?
The current stock price of ORPH is 0.87 null. The price decreased by -2.25% in the last trading session.
What is the ticker symbol for ORPHAZYME A/S - ADR stock?
The exchange symbol of ORPHAZYME A/S - ADR is ORPH and it is listed on the Nasdaq exchange.
On which exchange is ORPH stock listed?
ORPH stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ORPHAZYME A/S - ADR stock?
9 analysts have analysed ORPH and the average price target is 15.81 null. This implies a price increase of 1717.72% is expected in the next year compared to the current price of 0.87. Check the ORPHAZYME A/S - ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ORPHAZYME A/S - ADR worth?
ORPHAZYME A/S - ADR (ORPH) has a market capitalization of 30.72M null. This makes ORPH a Nano Cap stock.
How many employees does ORPHAZYME A/S - ADR have?
ORPHAZYME A/S - ADR (ORPH) currently has 180 employees.
What are the support and resistance levels for ORPHAZYME A/S - ADR (ORPH) stock?
ORPHAZYME A/S - ADR (ORPH) has a resistance level at 0.9. Check the full technical report for a detailed analysis of ORPH support and resistance levels.
Should I buy ORPHAZYME A/S - ADR (ORPH) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ORPH, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ORPH, evaluating the profitability, health, valuation and growth aspects
- ORPHAZYME A/S - ADR (ORPH) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ORPHAZYME A/S - ADR (ORPH) Sales and EPS estimates to see what analysts future expectations are.
- ORPHAZYME A/S - ADR (ORPH) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ORPHAZYME A/S - ADR (ORPH) Insider and Institutional Ownership to learn about the owners and their transactions.
- ORPHAZYME A/S - ADR (ORPH) Stock Chart to make your own analysis
- ORPHAZYME A/S - ADR (ORPH) Latest news and press-releases to stay up to date.
Does ORPHAZYME A/S - ADR (ORPH) stock pay dividends?
ORPH does not pay a dividend.
What is the Price/Earnings (PE) ratio of ORPHAZYME A/S - ADR (ORPH)?
ORPHAZYME A/S - ADR (ORPH) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.79).
ORPH Technical Analysis
ORPH Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ORPH. ORPH may be in some trouble as it scores bad on both profitability and health.
ORPH Financial Highlights
Over the last trailing twelve months ORPH reported a non-GAAP Earnings per Share(EPS) of -3.79. The EPS decreased by -37.51% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -6429.52% | ||
| ROA | -197.56% | ||
| ROE | N/A | ||
| Debt/Equity | 0.14 |
ORPH Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 38% to ORPH. The Buy consensus is the average rating of analysts ratings from 9 analysts.